TMA includes several severe conditions such as thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), which can be life-threatening if not promptly diagnosed and treated. Understanding the mechanisms underlying TMA can provide insights into broader aspects of vascular biology, coagulation pathways, and immune responses, contributing to the development of new treatments not only for TMA but also for other related conditions. TMA can present with nonspecific symptoms and mimic other disorders, making diagnosis challenging. Research in this area aims to improve diagnostic strategies and biomarkers for early detection. Research in TMA has led to the development of targeted therapies, such as plasma exchange for TTP and eculizumab for atypical HUS, highlighting the importance of ongoing studies for further therapeutic advancements. Understanding the epidemiology of TMA, including risk factors and outcomes, is crucial for public health planning and resource allocation Studying TMA can lead to improved management strategies, resulting in better outcomes and quality of life for affected individuals. Overall, research on thrombotic microangiopathy is essential for advancing our understanding of this complex group of disorders and improving clinical outcomes for patients. 

DESCRIPTION OF STUDY

Patients will be recruited based on the above mentioned inclusion and exclusion criteria and after taking consent. Case history will be recorded in the proforma . Detailed medical history will be obtained regarding present complaints. Hematological and biochemical parameters will be recorded as per proforma and analyzed. The course of treatment during hospital stay will be analyzed and type of treatment the patient received will be recorded The outcome of the treatment given at the time of discharge will be recorded. The data collected will be analyzed using appropriate statistical methods.  No additional tests will be done